Sarepta Therapeutics, Inc. (BVMF:S1RP34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 10.04B -70.8% |
| Revenue (ttm) | 11.39B -2.2% |
| Net Income | 339.38M |
| EPS | 3.33 |
| Shares Out | n/a |
| PE Ratio | 29.60 |
| Forward PE | 7.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,097 |
| Open | 5.050 |
| Previous Close | 5.100 |
| Day's Range | 4.650 - 5.050 |
| 52-Week Range | 2.880 - 12.120 |
| Beta | 0.26 |
| RSI | 47.29 |
| Earnings Date | May 6, 2026 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
News
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
Reports Q1 revenue $730.8M, consensus $475.01M. “We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we beli...
Sarepta Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw stabilized operations, strong cash reserves, and positive operating profit, with ELEVIDYS and PMO franchises performing steadily. Promising siRNA pipeline data and expanded commercial initiatives support full-year guidance of $1.2–$1.4 billion.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "W...
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasd...
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying Roche’s (RHHBY) new placebo-controlled Phase 3 study raises the risk that Elevidys…
Sarepta price target raised to $19 from $18 at RBC Capital
RBC Capital raised the firm’s price target on Sarepta (SRPT) to $19 from $18 and keeps a Sector Perform rating on the shares as part of the firm’s broader research…
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously ap...
Deutsche ups Sarepta target, says 35% stock rally overdone
Deutsche Bank raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive preliminary data for…
Sarepta price target raised to $35 from $29 at Wedbush
Wedbush raised the firm’s price target on Sarepta (SRPT) to $35 from $29 and keeps an Outperform rating on the shares after including SRP-1001 for facioscapulohumeral muscular dystrophy and SRP-1003…
Sarepta price target raised to $13 from $9 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Sarepta (SRPT) to $13 from $9 and keeps a Sell rating on the shares. The firm says yesterday’s “positive” Phase…
Sarepta price target raised to $25 from $20 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Sarepta (SRPT) to $25 from $20 and keeps an Equal Weight rating on the shares. Early Phase 1/2 data in facioscapulohumeral muscular…
Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
After Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases, Leerink analyst Joseph Schwartz said the initial siRNA data in DM1 and…
Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
Oppenheimer analyst Kostas Biliouris says Sarepta’s (SRPT) myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy data “appear promising.” However, the early nature of data and use of di...
Sarepta Therapeutics Transcript: Study result
Preliminary phase I/II data for SRP-1001 (FSHD) and SRP-1003 (DM1) show robust, dose-dependent muscle delivery, strong gene knockdown, and favorable safety profiles. Both programs plan to advance to phase III in 2027, with more MAD data expected later this year.
Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
Sarepta (SRPT) Therapeutics shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapul...
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA p...
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Easter...
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
Oppenheimer analyst Andreas Argyrides notes that Sarepta’s (SRPT) management plans to submit an sNDA for Amondys/Vyondys before May 2026. The firm sees the sNDA filing as positive as it removes…
Sarepta provides regulatory update on Amondys 45, Vyondys 53
Sarepta (SRPT) provided an update on its ongoing regulatory interactions with the FDA regarding Amondys 45 and Vyondys 53 for the treatment of Duchenne muscular dystrophy. Sarepta requested a meeting…
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions...
Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
Sarepta (SRPT) announced screening and enrollment are underway in Cohort 8 of the ENDEAVOR study. The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an…
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort...
Sarepta price target raised to $31 from $26 at Mizuho
Mizuho raised the firm’s price target on Sarepta (SRPT) to $31 from $26 and keeps an Outperform rating on the shares. The firm updated the company’s model to incorporate its…
Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Revenue guidance for 2026 remains strong, with ELEVIDYS and PMO franchises supported by robust clinical data and ongoing sales force expansion. Key clinical milestones for DM1, FSHD, and nonambulant ELEVIDYS are on track, while pivotal trials and manufacturing scale-up are targeted for 2027.
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne ...